Skip to main content
Premium Trial:

Request an Annual Quote

Chinese Firm Builds Genomics Facility for Translational Research with PacBio as Major Platform


NEW YORK (GenomeWeb) − The Suqian Lakeside Pangu Gene Company in Tianjin, China, has established a new genomics facility for translational medicine research projects.

The company plans to focus on molecular-based approaches for the early diagnosis of cancer and disease recurrence, and on drug efficacy evaluation.

The new facility, located in the Tianjin Dong Li Lake Technology Park, has 1,500 square meters of lab space and will be using Pacific Biosciences' PacBio RS II as its major sequencing platform, the two firms said this week. Earlier this year, SLPC purchased four PacBio RS II systems, which were recently installed.